Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27800067 | 0.82 | XDH (0.44) | XDHDPP4PDPK1GDAADORA3 | |
| SCHEMBL37384 | 0.79 | DPP4 (0.66) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL20611894 | 0.79 | PDPK1 (0.44) | XDHDPP4PDPK1GDAADORA3 | |
| SCHEMBL29366073 | 0.79 | PDPK1 (0.44) | XDHDPP4PDPK1GDAADORA3 | |
| SCHEMBL8719273 | 0.78 | DPP4 (0.63) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL11456967 | 0.78 | DPP4 (0.63) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| Hydrochloric Acid SCHEMBL4763244 | 0.78 | DPP4 (0.63) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL24500763 | 0.76 | XDH (0.56) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL5935896 | 0.76 | CDK2 (0.61) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL1193371 | 0.76 | PDPK1 (0.41) | XDHDPP4PDPK1GDAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844063-A4 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2009-06-17 | — | — | EP | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | disclosed |
| EP-1844063-A1 | PURINE NUCLEOSIDE ANALOGS | Uti Limited Partnership (CA) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081665-A1 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | PNP, MTAP, TYMP | XDH 238/4885DPP4 365/4885KDM4E 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.